Paxil product liability claims
GlaxoSmithKline has settled more than 90% of the product liability claims against Paxil (paroxetine) related to discontinuation symptoms. As part of the settlements, "most" of the pending class action suits concerning discontinuation symptoms are being dismissed, firm says. GSK maintains it did not "admit liability with respect to the allegations in any of the suits." Paxil's labeling was revised in December 2002 to include a precaution concerning "discontinuation of treatment" (1"The Pink Sheet" Aug. 22, 2002, p. 21)...
You may also be interested in...
A suit regarding claims in Paxil TV ads could produce a court ruling regarding FDA's authority to regulate advertising
Notified bodies’ efforts to enhance a harmonized approach to remote audits have failed, raising questions about whether there is any avenue left to get vital devices certified by the 26 May EU MDR deadline.
As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.